Selinexor Intermediate Synthesis Without Isolation for High Z-Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing synthesis methods for selinexor and its intermediates are inefficient for commercial manufacturing due to the need for multiple purification steps, such as chromatography and crystallization, which are not suitable for large-scale production.
Innovation Solution
A novel process involving the reaction of compounds represented by structural formulas (I) and (II) in the presence of a catalyst, organic base, and ether-containing solvent, followed by reaction with an inorganic base in isopropyl alcohol, eliminates intermediate isolation and achieves high yield and stereoselectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If multiple purification steps (chromatography and crystallization) are used to achieve high Z-isomeric content, then product purity is improved, but manufacturing efficiency and scalability deteriorate
Solution Approach 1:
The patent changes the chemical parameters of the reaction system by introducing specific catalysts (e.g., DABCO, DBU, TBDM) and adjusting reaction conditions (temperature, solvent type, base equivalents) to achieve high Z-isomeric content (95:5 or greater) directly in the reaction mixture, eliminating the need for subsequent purification steps while maintaining manufacturing efficiency
Solution Approach 2:
The patent performs the stereoselective reaction in advance with optimized conditions to directly produce the desired Z-isomer as the major product. By preliminary optimizing the reaction parameters (catalyst selection, base equivalents, temperature control), the need for later purification is eliminated, improving overall manufacturing efficiency
2Manufacturing precision
If multiple purification steps are implemented to ensure high Z-isomeric content, then product quality is improved, but process complexity increases
Solution Approach 1:
The patent merges the reaction and purification steps into a single integrated process. By combining the stereoselective reaction conditions with direct product formation, the multiple separate steps (reaction → purification → isolation) are merged into one streamlined process, reducing equipment requirements and operational complexity while maintaining high Z-isomeric content
3Manufacturing precision
If conventional purification methods are used for intermediate isolation, then intermediate purity is improved, but production time and cost increase
Solution Approach 1:
The patent maintains continuous useful action by eliminating intermediate isolation and purification steps. The reaction mixture proceeds directly to the next transformation step without interruption for purification, maintaining continuous production flow and reducing overall production time while achieving the required intermediate purity through optimized reaction conditions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process provides a more efficient and scalable synthesis of selinexor intermediates with improved yield and stereoselectivity, reducing the need for intermediate isolation steps.
Implementation Method 1
reacting a compound represented by structural formula (I) with a compound represented by structural formula (II), in the presence of a catalyst, an organic base, and an ether-containing solvent under conditions suitable to produce a compound represented by structural formula (IIIa)
Implementation Method 2
reacting the compound represented by structural formula (IIIa) with an inorganic base in the presence of isopropyl alcohol (IPA) under conditions suitable to produce a compound represented by structural formula (III)
Data Source
AI summary
The present invention provides an improved process for preparation of the (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylic acid (referred to as compound of the structural formula (III)), which is a useful key intermediate for the synthesis of Selinexor ((Z)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide). The process comprises reaction of the compound of the structural formula (I) (as described herein) with the compound of the structural formula (II) (as described herein) in the presence of a catalyst, an organic base and an ether-containing solvent. The subsequent hydrolysis of the formed compound of the structural formula (IIIa) (as described herein) is performed without isolation of the compound of the structural formula (IIIa), providing compound of the structural formula (III) in high yield and stereoselectivity.